



BRIAN SANDOVAL  
*Governor*

STATE OF NEVADA  
DEPARTMENT OF HEALTH AND HUMAN SERVICES  
**DIVISION OF HEALTH CARE FINANCING AND POLICY**  
1100 E. William Street, Suite 101  
Carson City, Nevada 89701  
[www.dhcfp.nv.gov](http://www.dhcfp.nv.gov)

MICHAEL J. WILLDEN  
*Director*

LAURIE SQUARTSOFF  
*Administrator*

**Nevada Medicaid  
Drug Use Review (DUR) Board  
Agenda**

The Division of Health Care Financing and Policy (DHCFP) Drug Use Review (DUR) Board will conduct a public meeting on April 24, 2014 beginning at 5:30 pm at the following location:

**BEST WESTERN AIRPORT PLAZA HOTEL  
1981 TERMINAL WAY  
RENO, NV 89502-3215**

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Rita Mackie at: 775-684-3681 or email: [rmackie@dhcfp.nv.gov](mailto:rmackie@dhcfp.nv.gov) in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Meeting material may be found at: <http://www.medicaid.nv.gov/providers/rx/rxmeetings.aspx>

**Items may be taken out of order.**

**Items may be combined for consideration by the public body.**

**Items may be pulled or removed from the agenda at any time.**

**Public comment is limited to 5 minutes per individual, organization, or agency, but may be extended at the discretion of the Chairperson.**

**1) Call to Order and Roll Call**

**2) Public Comment**

**No action may be taken on a matter raised under this item of the agenda until the matter itself has been specifically included on the agenda as an item upon which action can be taken.**

**3) Administrative**

- a) For Possible Action: Review and approve January 23, 2014 Meeting Minutes
- b) Status Update by DHCFP
  - i) Public Comment
  - ii) Program Updates

1. Health Care Reform

**4) Clinical Presentations**

- a) Presentation of sofosbuvir utilization and clinical information
  - i) Public Comment
  - ii) Discussion by Board on Review of Utilization Data
  - iii) **For Possible Action:** Adoption of Clinical Prior Authorization Criteria
  
- b) Presentation of Hepatitis C Protease Inhibitors utilization and clinical information
  - i) Public Comment
  - ii) Discussion by Board on Review of Utilization Data
  - iii) **For Possible Action:** Adoption of updated Clinical Prior Authorization Criteria
  
- c) Presentation of palivizumab utilization and clinical information
  - i) Public Comment
  - ii) Discussion by Board on Review of Utilization Data
  - iii) **For Possible Action:** Adoption of updated Clinical Prior Authorization Criteria.
  
- d) Presentation of proton pump inhibitor use and clinical information
  - i) Public Comment
  - ii) Discussion by Board on Review of Utilization Data
  - iii) **For Possible Action:** Adoption of updated Clinical Prior Authorization Criteria and/or Quantity Limits
  
- e) Presentation of immunomodulators use and clinical information
  - i) Public Comment
  - ii) Discussion by Board on Review of Utilization Data
  - iii) **For Possible Action:** Adoption of updated Clinical Prior Authorization Criteria.
  
- f) Presentation of products used to treat ADD/ADHD use and clinical information
  - i) Public Comment
  - ii) Discussion by Board on Review of Utilization Data
  - iii) **For Possible Action:** Adoption of updated Clinical Prior Authorization Criteria
  
- g) Review of transdermal fentanyl use and clinical information
  - i) Public Comment
  - ii) Discussion by Board on Review of Utilization Data
  - iii) **For Possible Action:** Adoption of updated Clinical Prior Authorization Criteria
  
- h) Presentation of botulinum toxin products use and clinical information
  - i) Public Comment
  - ii) Discussion by Board on Review of Utilization Data
  - iii) **For Possible Action:** Adoption of Clinical Prior Authorization Criteria

- i) Presentation of buprenorphine and buprenorphine/naloxone use and clinical information
  - i) Public Comment
  - ii) Discussion by Board on Review of Utilization Data
  - iii) **For Possible Action:** Adoption of updated Clinical Prior Authorization Criteria and/or quantity limits
  
- j) Presentation of Hydrocodone ER (Zohydro®) use and clinical information
  - i) Public Comment
  - ii) Discussion by Board on Review of Utilization Data
  - iii) **For Possible Action:** Adoption of Clinical Prior Authorization Criteria and/or quantity limits

## 5) DUR Board Requested Reports

- a) Special Presentation: Clinical Steering Committee Presentation
  - i) Public comment
  - ii) Discussion by the Board on Presentation
  - iii) **For Possible Action by the Board**
  
- b) Report on Top 10 Black Box warning medications:
  - i) Public comment
  - ii) Discussion by Board on Review of Utilization Data
  - iii) **For Possible Action by the Board**
  
- c) Report on Controlled Substance utilization and trends
  - i) Public comment
  - ii) Discussion by Board on Review of Utilization Data
  - iii) **For Possible Action by the Board**
  
- d) Report on psychotropic drug use in children
  - i) Public comment
  - ii) Discussion by Board on Review of Utilization Data
  - iii) **For Possible Action by the Board**
  
- e) Report on Promethazine VC use
  - i) Public comment
  - ii) Discussion by Board on Review of Utilization Data
  - iii) **For Possible Action by the Board**
  
- f) Report on Blood Factor Product utilization
  - i) Public comment
  - ii) Discussion by Board on Review of Utilization Data
  - iii) **For Possible Action by the Board**

- g) Report on Abilify Utilization by age and diagnosis
  - i) Public Comment
  - ii) Discussion by Board on Review of Utilization Data
  - iii) **For Possible Action by the Board**
- h) Report on ProDUR edit on late refill
  - i) Public Comment
  - ii) Discussion by Board on Review of Utilization Data
  - iii) **For Possible Action by the Board**
- i) Report on seizure medication utilization and patient compliance
  - i) Public Comment
  - ii) Discussion by Board on Review of Utilization Data
  - iii) **For Possible Action by the Board**

## 6) Standard DUR Reports

- a) Review of Prescribing/Program Trends
  - i) Program Trends
  - ii) Top 10 Therapeutic Classes for Q3 2013, Q4 2013, and Q1 2014 (by Payment and by Claims)
  - iii) Top 50 Drugs of Q3 2013, Q4 2013, and Q1 2014 (by Payment and by Claims)
- b) Concurrent Drug Utilization Review (ProDUR)
  - i) Review of Q3 2013, Q4 2013, and Q1 2014
  - ii) Review of Top Encounters by Problem Type
- c) Retrospective Drug Utilization Review (RetroDUR)
  - i) Public Comment
  - ii) Review of Responses
  - iii) Status of Previous Quarter
  - iv) Status of Current Quarter
  - v) **For Possible Action:** Board Discussion and Approval of Future Criteria Selection

## 7) Closing Discussion

- a) Public Comment
- b) Date, Time and Location of next meeting
- c) Adjournment

This notice and agenda has been posted on or before 9:00 am on the third working day before the meeting at the following locations:

Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site ([www.medicaid.nv.gov](http://www.medicaid.nv.gov)).

Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill Country Library; Las Vegas Library; Douglas County Library; Elko County Library, Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the action items will be mailed to you or they may be reviewed Monday through Friday from 9:00 until 5:00 pm or at the meeting. Please call at least one day ahead for an appointment for document review. You may request meeting material or provide written comments by writing to Rita Mackey, DHCFP, 1100 E. William Street, Suite 102, Carson City, NV 89701.

All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.

Anyone presenting documents for consideration during the public comment portion of the meeting must provide sufficient copies for each member of the committee and the official record. Copies are to be distributed at the time of the meeting and should be provided at meeting locations; DHCFP or its contractor will not distribute public comment information or materials prior to the public meeting.